Literature DB >> 26658239

Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.

Ying Zhang1, Alicia J Jenkins2, Arpita Basu3, Julie A Stoner1, Maria F Lopes-Virella4, Richard L Klein4, Timothy J Lyons5.   

Abstract

Our objective is to define differences in circulating lipoprotein subclasses between intensive versus conventional management of type 1 diabetes during the randomization phase of the Diabetes Control and Complications Trial (DCCT). NMR-determined lipoprotein subclass profiles (NMR-LSPs), which estimate molar subclass concentrations and mean particle diameters, were determined in 1,294 DCCT subjects after a median of 5 years (interquartile range: 4-6 years) of randomization to intensive or conventional diabetes management. In cross-sectional analyses, we compared standard lipids and NMR-LSPs between treatment groups. Standard total, LDL, and HDL cholesterol levels were similar between randomization groups, while triglyceride levels were lower in the intensively treated group. NMR-LSPs showed that intensive therapy was associated with larger LDL diameter (20.7 vs. 20.6 nm, P = 0.01) and lower levels of small LDL (median: 465 vs. 552 nmol/l, P = 0.007), total IDL/LDL (mean: 1,000 vs. 1,053 nmol/l, P = 0.01), and small HDL (mean: 17.3 vs. 18.6 μmol/l, P < 0.0001), the latter accounting for reduced total HDL (mean: 33.8 vs. 34.8 μmol/l, P = 0.01). In conclusion, intensive diabetes therapy was associated with potentially favorable changes in LDL and HDL subclasses in sera. Further research will determine whether these changes contribute to the beneficial effects of intensive diabetes management on vascular complications.

Entities:  

Keywords:  atherosclerosis; clinical trial; dyslipidemia; high density lipoprotein; intensive diabetes treatment; low density lipoprotein; nuclear magnetic resonance

Mesh:

Substances:

Year:  2015        PMID: 26658239      PMCID: PMC4727426          DOI: 10.1194/jlr.P060657

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  50 in total

1.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

Review 2.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

3.  Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group.

Authors: 
Journal:  Clin Chem       Date:  1987-12       Impact factor: 8.327

4.  The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification.

Authors:  H M Colhoun; M B Rubens; S R Underwood; J H Fuller
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

5.  The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group.

Authors: 
Journal:  Diabetes       Date:  1986-05       Impact factor: 9.461

6.  The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  1995-01

7.  Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association/American College of Cardiology guidelines: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Brian T Steffen; Weihua Guan; Alan T Remaley; Pathmaja Paramsothy; Susan R Heckbert; Robyn L McClelland; Philip Greenland; Erin D Michos; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-12-04       Impact factor: 8.311

Review 8.  Vascular memory: can we broaden the concept of the metabolic memory?

Authors:  György Jermendy
Journal:  Cardiovasc Diabetol       Date:  2012-04-30       Impact factor: 9.951

9.  Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study.

Authors:  David M Nathan; Paula McGee; Michael W Steffes; John M Lachin
Journal:  Diabetes       Date:  2013-08-29       Impact factor: 9.461

10.  Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.

Authors:  John M Lachin; Neil H White; Dean P Hainsworth; Wanjie Sun; Patricia A Cleary; David M Nathan
Journal:  Diabetes       Date:  2014-09-09       Impact factor: 9.461

View more
  6 in total

1.  Risk Factors for Kidney Disease in Type 1 Diabetes.

Authors:  Bruce A Perkins; Ionut Bebu; Ian H de Boer; Mark Molitch; William Tamborlane; Gayle Lorenzi; William Herman; Neil H White; Rodica Pop-Busui; Andrew D Paterson; Trevor Orchard; Catherine Cowie; John M Lachin
Journal:  Diabetes Care       Date:  2019-03-04       Impact factor: 19.112

Review 2.  The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it.

Authors:  Alicia Jenkins; Andrzej Januszewski; David O'Neal
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-02-13

Review 3.  Diabetes Dyslipidemia.

Authors:  Jonathan D Schofield; Yifen Liu; Prasanna Rao-Balakrishna; Rayaz A Malik; Handrean Soran
Journal:  Diabetes Ther       Date:  2016-04-07       Impact factor: 2.945

4.  The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.

Authors:  Trevor J Orchard; Bertrand Cariou; Margery A Connelly; James D Otvos; Shuyu Zhang; Caryl J Antalis; Tibor Ivanyi; Byron J Hoogwerf
Journal:  Cardiovasc Diabetol       Date:  2017-06-06       Impact factor: 9.951

5.  Potential Application of 1H NMR for Routine Serum Lipidome Analysis -Evaluation of Effects of Bariatric Surgery.

Authors:  Adriana Mika; Zbigniew Kaczynski; Piotr Stepnowski; Maciej Kaczor; Monika Proczko-Stepaniak; Lukasz Kaska; Tomasz Sledzinski
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

6.  Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study.

Authors:  Evgenia Gourgari; Martin P Playford; Umberto Campia; Amit K Dey; Fran Cogen; Stephanie Gubb-Weiser; Mihriye Mete; Sameer Desale; Maureen Sampson; Allen Taylor; Kristina I Rother; Alan T Remaley; Nehal N Mehta
Journal:  Cardiovasc Diabetol       Date:  2018-12-19       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.